Valneva said Wednesday that its single-shot chikungunya vaccine candidate induced protective neutralizing antibody titers in more than 96% of patients 6 months after vaccination in a phase 3 trial.
The trial assessed the vaccine, VLA1553, among 4,115 adults aged 18 years or older at 44 sites in the United States. Valneva said the trial met its primary endpoint, with the vaccine inducing protective neutralizing antibody titers in 98.9% of participants at 1 month (95% CI, 96.7-99.8) and 96.3% of participants at 6 months (95% CI, 93.1-98.3).
Valneva previously reported interim data from the trial